Horizon Therapeutics completed the acquisition of Viela Bio for $3.1bn.

Horizon Therapeutics, a biopharmaceutical company, completed the acquisition of Viela Bio, a clinical-stage biotechnology company, for $3.1bn. "The Viela acquisition provides multiple opportunities to drive long-term growth and solidify our future as an innovation-driven biotech company. With its deep, mid-stage biologics pipeline, strong R&D team and on-market medicine UPLIZNA®, Viela is a strong complementary strategic fit with our pipeline, commercial portfolio and therapeutic areas of focus. It also gives us tremendous potential to make an even greater impact on the lives of people with rare, autoimmune and severe inflammatory diseases," Tim Walbert, Horizon Chairman, President and CEO.